DOSSIER · 13F-HR · Q2 2026

BIOS Capital Management, LP

$42M in tracked AUM across 9 positions as of Q2 2026.

BC
CIK 0001813845 · last filed Jun 30, 2026
Total AUM
$42M
as of Q2 2026
Holdings
9
positions
Whale Score
63
63
tracked
Activity
no data
changes this Q
AI Analysis · Q2 2026
Portfolio Overview

As of 2025-09-30 BIOS Capital Management reports a total 13F portfolio value of $21.06 million across 6 reported holdings. That represents a 71.0% decline from the prior quarter’s $72.58 million — a change driven almost entirely by liquidations rather than mark-to-market moves within the remaining names (see Quarter Changes). The portfolio is extremely concentrated: the top four positions account for effectively the entire portfolio (8.10 + 6.59 + 4.42 + 1.94 = $21.05M ≈ 100...

Key portfolio concentration metrics

  • Total value: $21.06M
  • Number of holdings: 6
  • Top 1 position (Cognition Therapeutics): 38.47% of portfolio
  • Top 2 positions: 69.78% of portfolio
  • Top 3 positions: 90.78% of portfolio
  • Top 4 positions: ~100% of portfolio
Key Holdings

The four largest positions (which make up essentially the whole portfolio) are:

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
ACTU
ACTUATE THERAPEUTICS INC
$15M10.0M36.9%
02
IRD
OPUS GENETICS INC
$15M3.7M36.3%
03
CGTX
COGNITION THERAPEUTICS INC
$7M6.0M16.6%
04
RNTX
REIN THERAPEUTICS INC
$3M3.0M7.4%
05
LTRN
LANTERN PHARMA INC
$1M249K2.5%
06
INAB
IN8BIO INC
$114K81K0.3%

Filing history

2026Q2Jun 30
$42M 21.2%
9 positionsView →
2026Q1Mar 31
$53M 36.0%
10 positionsView →
2025Q4Dec 31
$83M 292.4%
9 positionsView →
2025Q3Sep 30
$21M 71.0%
6 positionsView →
2025Q2Jun 30
$73M 573.9%
9 positionsLocked
2025Q1Mar 31
$11M 88.8%
6 positionsLocked
2024Q4Dec 31
$96M
9 positionsLocked